abbvie-gp1692
Phase 2
AbbVieabbvie-gp1692 is one of 41 therapeutic programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
125 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyPhase 3
Aldactone
PfizerPhase 3
Rifadin
SanofiPhase 3
Nolvadex
AstraZenecaPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Duvyzat
ItalfarmacoPhase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Creatine Monohydrate
MMassachusetts General Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for abbvie-gp1692. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company